Metabolic reprogramming has been proposed to be a hallmark of cancer. Aside from the glycolytic pathway, the metabolic changes of cancer cells primarily involve amino acid metabolism. However, in glioma, the characteristics of the amino acid metabolism-related gene set have not been systematically profiled. In the present study, RNA sequencing expression data from 309 patients in the Chinese Glioma Genome Atlas database were included as a training set, while another 550 patients within The Cancer Genome Atlas database were used to validate. Consensus clustering of the 309 samples yielded two robust groups. Compared with Cluster1, Cluster2 correlated with a better clinical outcome. We then developed an amino acid metabolism-related risk signature for glioma. Our results showed that patients in the high-risk group had dramatically shorter overall survival than low-risk counterparts in Moreover, univariate and multivariate analysis showed that the 30-gene signature was an independent prognostic factor for glioma. Furthermore, Gene Ontology analysis and Gene Set Enrichment Analysis showed that tumors with a high risk score correlated with various aspects of the malignancy of glioma. In summary, we demonstrated a novel amino acid metabolism-related risk signature for predicting prognosis for glioma.
| INTRODUC TI ON
Metabolic reprogramming, as both direct and indirect consequences of oncogenic mutations, has been proposed to be a hallmark of cancer. 1, 2 Amino acid metabolism might represent an "Achilles heel" in cancer as a number of tumors acquire an altered dependency on some of these metabolic pathways. [3] [4] [5] Amino acid metabolism involving serine, glycine and threonine and the carbon units they provide satisfies cell growth and proliferation, as well as the maintenance of cellular redox, genetic and epigenetic status. [6] [7] [8] Also, glutamine, as a super nutrient, plays surprising roles in supporting the biological hallmarks of malignancy. 9, 10 Additionally, which collectively contributed to antitumor responses in vitro and in mouse models in vivo. 13 Nevertheless, currently, the characteristic of the amino acid metabolism-related gene set has not been systematically profiled.
In our study, we focused on gliomas, the most common form of primary malignant brain tumor, which can be subdivided into grades II-IV in light of WHO classification. Compared with WHO Grades II-III, which comprise LGG, GBM WHO IV bears a dismal prognosis with median survival rates of 14.6 months. [14] [15] [16] The
WHO classification of central nervous system (CNS) tumors
combines molecular parameters and histology to define diffuse gliomas. 17 GBM with wild-type IDH (GBM-IDHwt); and (v) GBM with IDH mutation (GBM-IDHmut). 18, 19 These five subtypes of glioma show distinct tumor characteristics and OS outcomes.
In the present study, we conducted systematic and comprehensive research on the characteristics of the amino acid metabolism- 
| Bioinformatics analysis
We carried out consensus clustering with the R programming lan- org/gsea/index.jsp) was carried out to determine whether confirmed gene sets were significantly distinct between the two groups (high risk score vs low risk score). 24, 26 We evaluated tumor purity of each sample using the ESTIMATE algorithm, which reflects the enrichment of stromal and immune cell gene signatures in a transcriptional profile. 27 Protein-protein interactions among 30 amino acid metabolism-related proteins were analyzed using the STRING database (http://www.string-db.org/). We then computed the risk score according to the formula followed in the training and validation datasets.
| Statistical analysis
On the basis of the median risk value, patients were separated into high-and low-risk groups in both CGGA and TCGA databases.
Kaplan-Meier survival curves and the log rank test were exploited to evaluate the prognostic significance. Figure S1 ). We observed that consensus clustering determined striking differences in the clinical and molecular features of the two glioma subclasses ( Figure 1E , Table S1 ). In the training cohort, Cluster1 was strongly linked with older age at diagnosis (median age = 46, P < .001), classical or mesenchymal subtypes (72.3%, P < .001), GBM phenotype (71.8%, P < .001), IDH wild type (72.9%, P < .001) and 1p/19q noncodeletion (96.3%, P < .001). Cluster2 cluster mainly represented the proneural or neural subtypes (92.0%, P < .001), lower grade (88.5%, P < .001), and IDH mutational status (81.3%, P < .001). These findings were validated in the TCGA datasets ( Figure S2 ). Furthermore, OS analysis showed that glioma patients with the Cluster1 subgroup had a better prognosis compared with the Cluster2 subgroup (P < .001, log-rank; Figure 1F ). These results indicated that amino acid metabolism-related gene sets were involved in the malignancy of gliomas and closely related to prognosis of patients. According to the CGGA cohort, TCGA samples were also clearly stratified into two different prognostic subgroups ( Figure S2F ).
| Identification of a 30-gene risk signature associated with amino acid metabolism
To identify an amino acid metabolism-related gene signature, first, we selected 121 genes associated with OS (P < .05) by univariate Cox regression analysis in the training cohort. Then, by LASSO regression algorithm, 30 genes were selected as active covariates to evaluate the prognostic value, and the risk scores for the patients in the training cohort were obtained (Figure 2A ,B). To assess performance of the signature genes as classifier, we distinguished the training dataset into high-risk and low-risk groups by using the median risk score as the cutoff value, and found a significant difference in the clinical and molecular features between the two groups ( Figure 2C and Table 1 ). In comparison with the low-risk group, patients in the high-risk group tended to be older (P < .001). As shown in Table 1, classical and mesenchymal subtypes were found in 12.9% and 73.5%
of low-risk and high-risk groups, respectively (P < .001). Moreover, we found that GBM accounted for a large proportion, 72.9% of the total, in the high-risk group, whereas GBM was 12.9% in the lowrisk group (P < .001). We found that 78.6% and 24.5% of samples in the low-risk and high-risk groups, respectively, were found to carry IDH mutations (P < .001). Loss of chromosome 1p/19q was found in 24.6% and 3.1% of low-risk and high-risk groups, respectively (P < .001). Our results also showed that MGMT promoter methylation was found in 70.6% and 42.8% of low-risk and high-risk groups, respectively (P < .001).
To validate the 30 amino acid metabolism-related risk signature in other populations, we formulated the risk scores for each patient in TCGA database based on the 30-gene coefficients derived from the training dataset. Consistent with the above results, we also found that there was significant difference between the two groups in an independent validation cohort ( Figure S3 and Table 1 ). In brief, compared to the low-risk group, the high-risk group tended to comprise the patients with poor prognostic features.
| Identification of 30-gene signature for prognostication in glioma
In view of the close correlation between risk groups and clinicopathological features, we sought to assess the prognostic value of the risk score. In all gliomas, patients were assigned to two groups according to the median risk score. Our results
showed that patients in the high-risk group (n = 155) had dramatically shorter OS than their low-risk counterparts (n = 154) in the training cohort (median OS = 9.0 vs 37.9 months; P < .0001; Figure 3A ). Moreover, we explored the prognostic value of risk
score in gliomas of different grades and found that OS differed significantly between high-risk and low-risk groups in WHO grade Given that these five glioma subtypes showed distinct tumor characteristics and OS outcomes, we determined whether the risk score had prognostic value in the five various populations. For LGG, survival time of the high-risk group was remarkably shorter than that of the low-risk group in LGG-IDHmut-noncodel (P < .0001; Figure 4A ) and
LGG-IDHwt (P < .0001; Figure 4B ), whereas there was no significant difference in LGG-IDHmut-codel (P = .1175; Figure 4C ). For both GBM-IDHwt and GBM-IDHmut, there were significant differences in OS between the two risk groups (P < .0001; P = .0015, respectively; Figure 4D ,E).
Meanwhile, the signature value showed significant differ- Therefore, we explored the distribution of TCGA subtypes for GBM in the CGGA and TCGA cohorts ( Figure 5F and Figure S5F ). 
TA B L E 1 Correlation between 30-gene-based risk scores and clinicopathological factors of glioma patients in the two cohorts

| Prognostic validity of the 30-gene signature for glioma
Subsequently, we investigated the specificity and sensitivity of risk score in the prediction of 3-and 5-year survival by analyzing the ROC curve, and compared the 30-gene signature with traditional "age" and "grade". The 30-gene signature showed striking prognostic validity, with AUC of 0.966 and 0.975 for 3-and 5-year survival, respectively, which were higher than for the traditional factors ( Figure 3E,F) , underscoring the superior predictive value of the 30-gene signature.
F I G U R E 3
Prognostic significance of the 30-gene signature-derived risk scores in different WHO grades. Prognosis efficiency of the 30-gene risk signature in all grades (A), grade II (B), grade III (C) and GBM (D) from the CGGA datasets. P-value shown in each panel is determined by a log-rank test between the two groups. E,F, ROC curves indicating the sensitivity and specificity of predicting 3-and 5-y survival with the amino acid metabolism-related signature in the CGGA datasets. CGGA, Chinese Glioma Genome Atlas; GBM, glioblastoma; OS, overall survival; ROC, receiver operating characteristic; WHO, World Health Organization
| Univariate and multivariate analysis shows prognostic value of 30-gene signature
To further explore whether the risk score was an independent prognostic factor of prognosis in glioma, we carried out univariate and Table 2 ). Consistently, the local immune-related risk signature was validated as an independent factor after Cox regression analyses in TCGA cohort (Table S2 ).
| Functional annotation of 30-gene signature
To explore the potentially altered functional characteristics associated with the 30-gene signature, GO analysis was carried out to study differences in biological processes between the two risk groups.
F I G U R E 4
Prediction of outcome in diverse cohorts stratified by IDH mutation and 1p/19q codeletion status. Kaplan-Meier survival curves for LGG patients with IDH-wild type (A), IDH-mutation but not the 1p/19q codeletion (B) and IDH-mutation with 1p/19q codeletion (C), classified into two groups based on 30-gene signature-derived risk scores. Kaplan-Meier survival curves also show the prognostic value of GBM patients with IDH-wild type (D) and IDH-mutation (E) in the CGGA cohort. P-value is the result of a log-rank test between the two groups shown in each panel. CGGA, Chinese Glioma Genome Atlas; Codel, codeletion; GBM, glioblastoma; IDH, isocitrate dehydrogenase;
LGG, lower-grade glioma; OS, overall survival LGG (E) and TCGA subtypes in GBM (F). *P < .05; **P < .01; ****P < .0001; ns, not significant. CGGA, Chinese Glioma Genome Atlas; Codel, codeletion; GBM, glioblastoma; IDH, isocitrate dehydrogenase; LGG, lower-grade glioma; TCGA, The Cancer Genome Atlas; WHO, World Health Organization First, we demonstrated 1346 high-risk score positively related genes (P < .05) and 922 negatively related genes (P < .05) using Pearson correlation analysis. Genes upregulated in the high-risk group were primarily involved in tumor progression, including "extracellular matrix organization", "cell division", "angiogenesis", "cell adhesion", "apoptotic process" and "immune response". In contrast, downregulated genes in the high-risk group were closely related to neurogenesis, such as "chemical synaptic transmission", "learning", "neurotransmitter secretion" and "nervous system development" ( Figure 6A ).
Moreover, GO analysis was implemented to explore the differences in KEGG pathway between the high-and low-risk score groups.
We found that positively related genes were mainly enriched in KEGG terms including "ECM-receptor interaction", "cell cycle", "focal adhesion" and "TNF signaling pathway", whereas the negatively correlated genes were enriched in terms including "retrograde endocannabinoid signaling", "insulin secretion" and "dopaminergic synapse" ( Figure 6B ).
These results were validated in TCGA cohort ( Figure S6 ).
Next, GSEA analyses were carried out for validation, showing that the high-risk groups were positively associated with regulation of innate immune response (P < .001) and response to tumor necrosis factor (P < .001), negatively with synaptic signaling (P < .001) and regulation of neurotransmitter levels (P < .001; Figure 6C ).
| D ISCUSS I ON
Fast-growing tumor cells largely draw energy out of typically increasing aerobic glycolysis, a phenomenon known as the Warburg effect. 1, 12 Aside from the glycolytic pathway, the metabolic changes of cancer cells primarily involve amino acid metabolism.
3
A previous study has identified a glucose-related risk signature for the malignancy of glioma and the survival of patients through bioinformatic profiling. 20 Also, metabolomic investigations have provided novel biomolecular insights into the aggressive phenotype of the malignancy of brain tumors. 24, 33, 34 However, there continues to be a gap in systematically understanding the characteristics of the amino acid metabolism-related gene set in glioma.
In the present study, for the first time, we built an amino acid metabolism-related risk signature to predict the prognosis of glioma.
RNAseq expression data from 309 patients in the CGGA database were included as the training set, whereas another 550 patients with TCGA database were used to validate. First, the 309 samples were apparently clustered into two distinct subclasses (k = 2), and the two subclasses showed significant differences in clinical and molecular features in both the CGGA and TCGA cohort. However, for k = 3, the area under the cumulative distribution function (CDF) curve was increased by more than 0.1-fold that of k = 2 ( Figure 1C,D) , and we found the ratio of samples in the third subclass was very small ( Figure 1B ). It also meant that for k > 2, clustering stability did not improve significantly.
Next, we developed a 30-gene-based risk signature to determine the status of amino acid metabolism in glioma patients. We observed that the high-risk group was closely associated with IDH wildtype, Table S3 , GBM patients in the CGGA cohort accounted for 44.7% of the total, whereas GBM accounted for a proportion of 26.9% in TCGA cohort.
LGG were divided into three subgroups based on the status of IDH and 1p/19q codeletion.
As for LGG-IDHwt, glioma patients in the high-risk group had a poorer prognosis than those with low-risk score, with a significant difference (P = .001). However, for LGG-IDHmut-codel and LGG-IDHmutnoncodel, the OS of high-risk patients tended to be worse, although the difference showed no significance (P > .05) ( Figure S4E-G) . We considered that if the sample sizes were increased, there might be a statistical difference in GBM and these subtypes.
Of note, we identified that the amino acid metabolism-related risk signature remained an independent prognostic factor after ad- OAT, GPT and BCAT2) among them participated in "cellular amino acid biosynthetic process". We still found some genes that played roles in certain amino acid metabolic processes. For instance, ODC1 took part in the "polyamine metabolic process", and AADAT and GCLC were involved in the "glutamate metabolic process". Moreover,
we analyzed the protein-protein interaction network for 30-amino acid metabolism-related genes/proteins using the STRING database ( Figure S8B ). Further molecular mechanisms as to how these genes affect the progression of glioma remain to be studied in our follow-up work.
In conclusion, we identified that the amino acid metabolismrelated gene set could distinguish the clinical and molecular features of gliomas. We then developed a 30-amino acid metabolism-related gene expression-based risk signature, which was strongly related to 
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